An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis

Circulation

Volumn 90, Issue 4 I, 1994, Pages 2051-2055

  Tanaka, Atsuo ^a   Matsumori, Akira ^a   Wang, Weizhong ^a   Sasayama, Shigetake ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

angiotensin; cardiomyopathy; myocarditis; viruses

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR; CANDESARTAN HEXETIL;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CELL INFILTRATION; CONTROLLED STUDY; ENCEPHALOMYOCARDITIS VIRUS; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HEART PROTECTION; MOUSE; MYOCARDITIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRUS REPLICATION;

EID: 0027962599     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.90.4.2051     Document Type: Article

References (42)

1. Chatterjee K, Parmly WW, Cohn JN, Levine TB, Awan NA, Mason DT, Faxon DP, Creager M, Gavras HP, Fauad FM, Tarazi RC, Hollenberg NK, Dzau V, LeJemtel TH, Sonnenblick EH, Turini GA, Brunner HR, the Captopril Multicenter Research Group I. Hemodynamic effects and long-term response. Am Heart J. 1985;110:439-447.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 1992;327: 685-691.
5. Matsumori A, Kawai C. An experimental model for congestive heart failure following encephalomyocarditis virus myocarditis in mice. Circulation. 1982;65:1230-1235.
6. Matsumori A, Kawai C. An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation. 1982;66:355-360.
7. Suzuki H, Matsumori A, Matoba Y, Kyu BS, Tanaka A, Fujita J, Sasayama S. Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis: An SH-dependent reduction of its expression and myocardial injury. J Clin Invest. 1993;91: 2727-2733.
8. Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther. 1993;266:114-120.
9. Matsumori A, Crumpacker CS, Abelmann WH. Treatment of viral myocarditis with ribavirin in an animal preparation. Circulation. 1985;71:834-839.
10. Dec GW, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DCS, Johnson RA. Active myocarditis in the spectrum of acute dilated cardiomyopathies. N Engl J Med. 1985;312:885-890.
11. Kawai C, Matsumori A, Fujiwara H. Myocarditis and dilated cardiomyopathy. Annu Rev Med. 1987;38:221-239.
12. Matoba Y, Matsumori A, Ohtani H, Tominaga M, Fujiwara H, Toyokuni S, Takahashi K, Midorikawa O, Kawai C. A case of biopsy-proven myocarditis progressing to autopsy-proven dilated cardiomyopathy. Clin Cardiol. 1990;13:732-737.
13. Zee-Chung C, Tsai CC, Palmer DC, Codd JE, Pennington DG, Williams GA. High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic congestive cardiomyopathy. J Am Coll Cardiol. 1984;3:63-70.
14. Bowles NE, Rose ML, Taylor P, Banner NR, Morgan-Capner P, Cunningham L, Archard LC, Yacoub MH. Endstage dilated car-diomyopathy: persistence of enterovirus RNA in myocardium at cardiac transplantation and lack of immune response. Circulation. 1989;80:1128-1136.
15. Kyu B, Matsumori A, Sato Y, Okada I, Chapman NM, Tracy S. Cardiac persistence of cardioviral RNA detected by polymerase chain reaction in a murine model of dilated cardiomyopathy. Circulation. 1992;86:522-530.
16. Mettaner B, Rouleau JL, Bichet D, Kortas C, Manzini C, Tremblay G, Chatterjee K. Differential long-term intrarenal and neurohumoral effects of captopril and prazosin in patients with congestive heart failure: importance of initial plasma renin activity. Circulation. 1986;73:492-502.
17. Riegger GAJ, Kochsiek K. Vasopressin, renin, and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1986;58:300-303.
18. Manthey J, Osterziel KJ, Rohrig N, Dietz R, Hackenthal E, Schmidt-Gayk H, Kubbler W. Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems. Am J Cardiol. 1987;59:171D-175D.
19. Daly P, Rouleau JL, Consineau D, Burgess JH, Chatterjee K. Effect of captopril and combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure. Br Heart J. 1986;56:152-157.
20. Francis GS. Neuroendocrine activity in congestive heart failure. Am J Cardiol. 1990;66:33D-39D.
21. Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson P, Sutton G. Clinical importance of the renin-angiotensin system in chronic heart failure: double-blind comparison of captopril and prazosin. BMJ. 1985;290:1861-1865.
22. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohumoral mechanisms in determining survival in patients with severe chronic heart failure. Circulation. 1987; 75(suppl IV):IV-80-IV-92.
23. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in altered renal function of congestive heart failure. Circ Res. 1984;55:669-675.
24. Fitzpatrick D, Nicholls MG, Ikram H, Espiner EA. Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br Heart J. 1983;50:163-169.
25. Dostal DE, Rothblum KN, Chemin MI, Cooper GR, Baker KM. Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. Am J Physiol. 1992; 263:C838-C850.
26. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990;86:1913-1920.
27. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1990;351:233-236.
28. Rogers TB, Gaa ST, Allen IS. Identification and characterization of functional angiotensin II receptors on cultured heart myocytes. J Pharmacol Exp Ther. 1986;236:438-444.
29. Dostal DE, Rothblum KN, Conrad KM, Cooper GR, Baker KM. Detection of angiotensin I and II in cardiac myocytes and fibroblasts. Am J Physiol. 1992;263:C851-C863.
30. Li C, Prakash O, Re RN. Altered regulation of angiotensin gene expression in the left ventricles of the hypertensive rats. Circulation. 1989;80(suppl II):II-450. Abstract.
31. Chordera A, Feller K. Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol. 1978;16:357-360.
32. Tan LB, Jalil JE, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-1195.
33. Kohara K, Mikami H, Okuda N, Higaki J, Ogihara T. Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Hypertension. 1993;21:975-979.
34. Ohkubo H, Kageyama R, Ujihara M, Hirose T, Inayama S, Nakanishi S. Cloning and sequence analysis of cDNA for rat angiotensinogen. Proc Natl Acad Sci USA. 1983;80:2196-2200.
35. 1-antitrypsin genes. J Biol Chem. 1984;259:8063-8065.
36. Fukamizu A, Takahashi S, Min SS, Tada M, Tanimoto K, Uehara S, Murakami K. Structure and expression of the human angiotensinogen gene. J Biol Chem. 1990;265:7576-7582.
37. Kageyama R, Ohkubo H, Nakanishi S. Induction of rat liver angiotensinogen mRNA following acute inflammation. Biochem Biophys Res Commun. 1985;129:826-832.
38. Ron D, Brasier AR, Wright KA, Tate JE, Habener JF. An inducible 50-kilodalton NF κ B-like protein and a constrictive protein both bind the acute-phase response element of the angiotensinogen. Mol Cell Biol. 1990;10:1023-1032.
39. Ganten D, Schelling P, Flügel RM, Fischer H. Effect of angiotensin and the angiotensin antagonist p 113 on iso-renin and cell growth in 3T3 mouse cells. Int Res Commun Med Sci. 1975;3:327.
40. Cambell-Boswell M, Robertson AL. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol. 1981;35:265-276.
41. Powell JS, Müller RKM, Rouge M, Kuhn H, Hefti F, Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol. 1990;16(suppl 4):S42-S49.
42. Scott-Burden T, Hahn AWA, Resink TJ, Bühler FR. Modulation of extracellular matrix by angiotensin II: stimulated glycoconjugate synthesis and growth in vascular smooth muscle cell. J Cardiovasc Pharmacol. 1990;16(suppl 4):S36-S41.